UnitedHealth price target raised to $660 from $650 at BofA

BofA raised the firm’s price target on UnitedHealth to $660 from $650 and keeps a Buy rating on the shares. As visibility continues to improve, BofA believes the focus will come back to the forward trajectory and UnitedHealth’s ability to grow EPS 13-16% for “years regardless of the macroeconomic backdrop,” the analyst tells investors. The firm is raising 2023 estimates and maintaining its above consensus 2024/2025 estimates after Q3 “brought back a familiar feeling of clean beats and raises” at UnitedHealth, the analyst added.